Skip to main content
HAE
NYSE Industrial Applications And Services

Haemonetics Q1 FY27: Revenue +5.6%, Adjusted EPS $1.14, Raises Full-Year Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$83.5
Mkt Cap
$3.799B
52W Low
$47.315
52W High
$88.585
52W Position info
76% above low
Off High info
5.7% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

HAE sits 76% above its 52-week low of $47.315.

Summary

Haemonetics reported Q1 FY27 revenue of $339.4 million, up 5.6%, with adjusted EPS of $1.14. The company raised its full-year revenue growth guidance to 5-8% and maintained margin and cash flow targets.


Key Events · Earnings and Guidance · HAE

  • Q1 Revenue and EPS Beat

    Revenue of $339.4 million grew 5.6% reported and 5.9% organic. Adjusted EPS of $1.14 exceeded expectations, driven by strength in Plasma and Blood Management Technologies.

  • Full-Year Guidance Raised

    Management lifted fiscal 2027 reported revenue growth guidance to 5-8% (from 4-7%) and organic growth to 4-7% (from 3-6%), while maintaining adjusted operating margin expansion of 50-100 bps and ~80% free cash flow conversion.

  • Strong Cash Flow Generation

    Operating cash flow was $52.3 million, up $34.9 million year-over-year, and free cash flow reached $39.1 million, up from $2.5 million, driven by favorable working capital and lower equipment transfers.

  • Segment Performance

    Apheresis revenue grew 5.3% reported (6.0% organic) led by Plasma up 7.2%. MedSurg grew 6.0% reported (5.9% organic) with Blood Management Technologies up 8.6% and Interventional Technologies returning to growth at 2.5%.


Analysis · HAE · Industrial Applications And Services

Haemonetics delivered a solid start to fiscal 2027 with 5.9% organic revenue growth and raised its full-year outlook. The guidance raise signals management confidence in sustained momentum across both Apheresis and MedSurg segments. Adjusted EPS of $1.14 beat expectations, and free cash flow improved sharply to $39 million from $2.5 million a year ago, strengthening the balance sheet. The stock is likely to react positively to the combination of a beat and a raise.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HAE was trading at $83.50 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $47.32 to $88.59. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HAE - Latest Insights

HAE
Nov 05, 2026, 6:13 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $127.42
Real-time Price: $122.86 info
Change: -$4.56 (-4%) info
Market Cap: $5.595B info
HAE
Nov 05, 2026, 6:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $127.42
Real-time Price: $122.86 info
Change: -$4.56 (-4%) info
Market Cap: $5.595B info
HAE
Oct 19, 2026, 4:15 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $118.73
Real-time Price: $122.86 info
Change: +$4.13 (+3%) info
Market Cap: $5.595B info
HAE
Oct 08, 2026, 3:50 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $101.71
Real-time Price: $122.86 info
Change: +$21.15 (+21%) info
Market Cap: $5.595B info
HAE
Aug 18, 2026, 6:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $96.06
Real-time Price: $122.86 info
Change: +$26.80 (+28%) info
Market Cap: $5.595B info